(Q40361792)

English

Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.

scientific article published on 14 October 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Matthias J. Schnell

8

object named as

Matthias J Schnell

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

James P McGettigan

1

object named as

James P McGettigan

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Bernhard Dietzschold

7

object named as

Bernhard Dietzschold

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Martin L Koser

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Philip M McKenna

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Mary Ellen Smith

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Julie M Marvin

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Laurence C Eisenlohr

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

14 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

344

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

363-377

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Order of transcription of genes of vesicular stomatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Interleukin 2 plays a central role in Th2 differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Antibody-mediated clearance of viruses from the mammalian central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

The roles of interleukin 2 and interferon-gamma in human B cell activation, growth and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Manipulating the immune system: humoral versus cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Viral vectors as potential HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Infectious rabies viruses from cloned cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime–boost approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.09.004

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40361792&oldid=1898701656"